<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7162773\results\search\country\results.xml">
  <result pre="âˆ—âˆ—Dr Jinlyu Sun, No. 1 Shuaifuyuan Wangfujing Dongcheng District, Beijing," exact="China" post="100730; Tel.: +86-18611382050. sunjinlv@pumch.cn #Dr Taijiao Jiang, No. 9,"/>
  <result pre="Tel.: +86-13366191184. taijiao@ibms.pumc.edu.cn ##Dr Guogang Xu, 28 Fuxing Road, Beijing," exact="China" post="100853; Tel.: +86-010-66876407. guogang_xu@qq.com â€¡These authors contributed equally to"/>
  <result pre="have led to a near disappearance of new cases in" exact="China" post="included rapid sequencing of the virus to establish testing"/>
  <result pre="China. To stop transmission of the virus and save lives," exact="China" post="adopted strategies and tactics that included a nationwide directive"/>
  <result pre="including 212 of 233 (91.0%) countries and international conveyances. The" exact="United States" post="(560,402 cases), Spain (166,831 cases), Italy (156,363 cases), Germany"/>
  <result pre="(91.0%) countries and international conveyances. The United States (560,402 cases)," exact="Spain" post="(166,831 cases), Italy (156,363 cases), Germany (127,854 cases), and"/>
  <result pre="international conveyances. The United States (560,402 cases), Spain (166,831 cases)," exact="Italy" post="(156,363 cases), Germany (127,854 cases), and Iran (71,686 cases)"/>
  <result pre="United States (560,402 cases), Spain (166,831 cases), Italy (156,363 cases)," exact="Germany" post="(127,854 cases), and Iran (71,686 cases) are among the"/>
  <result pre="Spain (166,831 cases), Italy (156,363 cases), Germany (127,854 cases), and" exact="Iran" post="(71,686 cases) are among the hardest hit, but cases"/>
  <result pre="epidemic curves and major intervention measures that were implemented in" exact="China" post="are shown in FigureÂ 1 . Here is a"/>
  <result pre="COVID-19 epidemiology curves and major intervention measures implemented in China." exact="China" post="CDC, Chinese Center for Disease Control and Prevention; NHC,"/>
  <result pre="Commission; WHO, World Health Organization. Data from the NHC, excluding" exact="Hong Kong" post="and Macau Special Administrative Regions and Taiwan. On December"/>
  <result pre="Health Organization. Data from the NHC, excluding Hong Kong and" exact="Macau" post="Special Administrative Regions and Taiwan. On December 31, 2019,"/>
  <result pre="of the National Institute of Viral Disease Control and Prevention.13" exact="China" post="informed the WHO. On January 10, 2020, the whole"/>
  <result pre="Several rapid and sensitive detection tests were developed by the" exact="China" post="CDC. On January 16, 2020, the National Health Commission"/>
  <result pre="Chinese guidance were more widely used in clinical practice in" exact="China" post="owing to its simplicity. According to the Chinese guidelines,20,89"/>
  <result pre="or lung transplant patients. ECMO has rarely been used in" exact="China" post="owing to limited resources.1,23 Moreover, there are no published"/>
  <result pre="specific information. â€¡The number of clinical trials of COVID-19 in" exact="China" post="as of April 3, 2020. Data from http://www.chictr.org.cn/. Xu"/>
  <result pre="However, the results of a clinical trial of lopinavir/ritonavir in" exact="China" post="showed no clear benefit beyond standard care in hospitalized"/>
  <result pre="approved for treatment of influenza on February 15, 2020, in" exact="China" post="and is being studied in COVID-19 clinical trials. The"/>
  <result pre="efficiently,40,44 and several clinical trials have been quickly conducted in" exact="China" post="to evaluate the efficacy and safety of chloroquine and"/>
  <result pre="modulators The results of laboratory findings of COVID-19 patients in" exact="China" post="showed an increase in plasma inflammatory cytokine levels, especially"/>
  <result pre="Queensland University in Australia, the National Institutes of Health in" exact="the United States," post="and the pharmaceutical companies Inovio and Moderna. On January"/>
  <result pre="University in Australia, the National Institutes of Health in the" exact="United States," post="and the pharmaceutical companies Inovio and Moderna. On January"/>
  <result pre="strain of SARS-CoV-2 was successfully isolated from patientsâ€™ samples in" exact="China" post="to provide the basis for vaccine development.69 On February"/>
  <result pre="Notice of COVID-19 â€¢Enforcement laws including â€œLaw of the Peopleâ€™s" exact="Republic of" post="China on the prevention and treatment of infectious diseases,â€�"/>
  <result pre="COVID-19 â€¢Enforcement laws including â€œLaw of the Peopleâ€™s Republic of" exact="China" post="on the prevention and treatment of infectious diseases,â€� â€œSurveillance"/>
  <result pre="and regions. We compare the epidemiologic characteristics among China, Italy," exact="South Korea," post="and the United States in FigureÂ 3 . The"/>
  <result pre="compare the epidemiologic characteristics among China, Italy, South Korea, and" exact="the United States" post="in FigureÂ 3 . The data from China show"/>
  <result pre="the epidemiologic characteristics among China, Italy, South Korea, and the" exact="United States" post="in FigureÂ 3 . The data from China show"/>
  <result pre="the United States in FigureÂ 3 . The data from" exact="China" post="show that the daily number of infected patients has"/>
  <result pre="are a steady daily number of imported cases. Similarly, in" exact="South Korea," post="the strategy that worked also included early testing, tracking,"/>
  <result pre="included early testing, tracking, and isolation. Unfortunately, lessons learned in" exact="China" post="have not been universally adopted, and the numbers of"/>
  <result pre="of SARS-CoV-2. Right, daily numbers of increasing cases. Data for" exact="China" post="were obtained from the National Health Commission of China,"/>
  <result pre="obtained from the National Health Commission of China, which excluded" exact="Hong Kong" post="and Macau Special Administrative Regions and Taiwan. Data for"/>
  <result pre="National Health Commission of China, which excluded Hong Kong and" exact="Macau" post="Special Administrative Regions and Taiwan. Data for the remaining"/>
  <result pre="obtained from the World Health Organisation. The lessons learned in" exact="China" post="and South Korea are that in these times of"/>
  <result pre="the World Health Organisation. The lessons learned in China and" exact="South Korea" post="are that in these times of crises, the earlier"/>
  <result pre="the earlier the intervention from a societal perspective the better." exact="China" post="had implemented an electronic monitoring system for infectious disease"/>
  <result pre="significant to evaluate the number and distribution of cases in" exact="China" post="as a basis for aggressive testing, tracking, and quarantining."/>
  <result pre="with continued closure of nonessential businesses. Conclusion The experience in" exact="China" post="is unique in that it was the first country"/>
  <result pre="to implement drastic measures to combat COVID-19. The strategy in" exact="China" post="was early testing, diligent tracking, and strict isolation of"/>
  <result pre="Even with this, there were more than 80,000 cases in" exact="China" post="and more than 3000 deaths. All countries, even China,"/>
  <result pre="China, can learn from this. Although the drastic measures that" exact="China" post="implemented appear for now to have stopped the viral"/>
  <result pre="part by the 10.13039/501100005089Beijing Municipal Natural Science Foundation General Program," exact="China" post="(7192197), CAMS Innovation Fund for Medical Sciences, China (2016-I2M-1-003),"/>
  <result pre="General Program, China (7192197), CAMS Innovation Fund for Medical Sciences," exact="China" post="(2016-I2M-1-003), the 10.13039/501100001809National Natural Science Foundation of China (31671371"/>
  <result pre="Medical Sciences, China (2016-I2M-1-003), the 10.13039/501100001809National Natural Science Foundation of" exact="China" post="(31671371 and 81700490), the Central Public-Interest Scientific Institution Basal"/>
  <result pre="and 81700490), the Central Public-Interest Scientific Institution Basal Research Fund," exact="China" post="(2016ZX310195, 2017PT31026, and 2018PT31016), and the Epidemic Research Project"/>
  <result pre="Research Project of Guangzhou Regenerative Medicine and Health Guangdong Laboratory," exact="China" post="(2020GZR110406001). Disclosures The authors have no conflicts of interest"/>
  <result pre="arm meta-analysis. [e-pub before print]. J Med Virol 10.1002/jmv.25735. 3collab:" exact="China" post="Centers for Disease ControlChina-WHO new coronavirus pneumonia (COVID-19) joint"/>
  <result pre="the 2019-nCoV epidemic?Lancet395202039139332035533 10collab: National Health Commission of the People's" exact="Republic of" post="China[New coronavirus pneumonia prevention and control program (seventh trial"/>
  <result pre="novel coronavirus genome identified in a cluster of pneumonia casesâ€&quot;Wuhan," exact="China" post="2019-2020China CDC Wkly220206162 14collab: The Joint Prevention and Control"/>
  <result pre="incubation period of COVID-19 infectionEClinicalMedicine202010033132292899 20National Health Commission of the" exact="People's Republic of China." post="Diagnosis and treatment protocol for novel coronavirus pneumonia (trial"/>
  <result pre="period of COVID-19 infectionEClinicalMedicine202010033132292899 20National Health Commission of the People's" exact="Republic of" post="China. Diagnosis and treatment protocol for novel coronavirus pneumonia"/>
  <result pre="Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan," exact="China" post="[e-pub before print]. Allergy, doi:10.1111/all.14238. 26ZhouF.YuT.DuR.Clinical course and risk"/>
  <result pre="drugs to treat coronavirus disease 2019 (COVID-19)Drug Discov Ther142020586032147628 43collab:" exact="China" post="National Health CommissionPress conference of the Joint Prevention and"/>
  <result pre="in patients with severe COVID-19 pneumonia: single-center experience from Wuhan," exact="China" post="[preprint]medRxiv202003.06.20032342 54ZhouW.LiuY.TianD.al. Potential benefits of precise corticosteroids therapy for"/>
  <result pre="32 recovered patients donate plasma to others with coronavirus infection." exact="China" post="Daily 2020 Feb 16. Available at: https://www.chinadaily.com.cn/a/202002/16/WS5e48cbf6a310128217277d72.html. Accessed February"/>
  <result pre="associated with clinical outcomes in 323 COVID-19 patients in Wuhan," exact="China" post="[e-pub before print]Clin Infect Dis202010.1093/cid/ciaa539 69Wu Z, McGoogan JM."/>
  <result pre="before print]. JAMA, doi:10.1001/jama.2020.2648. 70First vaccine clinical trials begin in" exact="the United States." post="March 17, 2020Available at:https://www.nature.com/articles/d41586-020-00154-wAccessed March 17, 2020 71China has"/>
  <result pre="print]. JAMA, doi:10.1001/jama.2020.2648. 70First vaccine clinical trials begin in the" exact="United States." post="March 17, 2020Available at:https://www.nature.com/articles/d41586-020-00154-wAccessed March 17, 2020 71China has"/>
  <result pre="treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adult in" exact="China" post="(2018 edition)Chin J Tuberc Respir Dis42018255280 79collab: Chinese Society"/>
  <result pre="during the first 50 days of the COVID-19 epidemic in" exact="China" post="[preprint]medRxiv202001.30.20019844 87collab: China National Health CommissionCovid-19 prevention and control"/>
  <result pre="50 days of the COVID-19 epidemic in China [preprint]medRxiv202001.30.20019844 87collab:" exact="China" post="National Health CommissionCovid-19 prevention and control schemeAvailable at:http://www.nhc.gov.cn/xcs/zhengcwj/202003/4856d5b0458141fa9f376853224d41d7.shtmlAccessed March"/>
 </snippets>
</snippetsTree>
